BioNTech reported better-than-expected first-quarter results
The shares of BioNTech SE (NASDAQ:BNTX) are inching higher ahead of the open, last seen up 0.8% at $137.20, after the pharma giant reported better-than-expected first-quarter earnings, as well as a revenue beat. The company said its quarterly revenues tripled during the quarter, thanks to strong Covid-19 vaccine sales, and stood by its 2022 vaccine revenue guidance.
BioNTech stock took a step back heading into 2022. It’s battled the $180 level multiple times over the course of the year, with the 80-day moving average thwarting BNTX’s most recent attempt to hold above the area. Fresh off of its third-straight weekly loss, the equity still has a lot of ground to cover if it wants to overcome its 41.3% year-to-date deficit.
Despite the negative price action of late, options traders have favored bullish bets. This is according to BioNTech stock’s 50-day call/put volume ratio at the International Securities Exchange (ISE), Cboe Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) of 1.72, which stands in the 80th percentile of its annual range. This indicates long calls are being picked up at a faster-than-usual clip.
It’s worth pointing out that BTNX ranks high on the Schaeffer’s Volatility Scorecard (SVS), with a score of just 99 out of 100, meaning the security has consistently realized bigger returns than its options implied volatility (IV) levels have priced in. In other words, it could be a strong candidate for premium-buying strategies moving forward.